Atorvastatin Improves the Propionic Acid- Induced Autism in Rats: The Roles of Sphingosine-1-Phosphate and Anti-inflammatory Action
![](/xmlui/themes/Mirage2//images/mime.png)
Erişim
info:eu-repo/semantics/openAccessTarih
2023Yazar
Durankus, FeritBudak, Korkut
Albayrak, Yakup
Sever, Ibrahim H.
Ozkul, Bahattin
Uyanikgil, Yigit
Albayrak, Neslihan
Üst veri
Tüm öğe kaydını gösterÖzet
Purpose The aim of this study is to investigate the benefits of atorvastatin on the propionic acid-induced autism model via increasing sphingosine-1-phosphate and anti-inflammatory actions with imaging and brain tissue investigations. Materials and methods Twenty-five mg/kg/day/rat of propionic acid (PPA) was administered intraperitoneally to 20 male Wistar rats, and 10 male Wistar rats were fed orally. Study groups were designed as follows: Group 1: Control Group (orally fed control, n=10); Group 2 (PPA+saline, n=10); Group 3 (PPA+Atorvastatin, n=10). The brain biochemical and histopathology assessments and magnetic resonance (MR) imaging were conducted across groups in order to compare them. Results The PPA+Atorvastatin group was found to have significantly lower levels of brain malondialdehyde, IL -2 level, IL-17, tumor necrosis factor-alpha (TNF-??), and lactate compared to the PPA+saline group. The PPA+Atorvastatin group had higher levels of nerve growth factor and nuclear factor erythroid 2-related factor 2 (NRF-2) and sphingosine-1-phosphate. In histopathology assessments, the PPA+Atorvastatin group was found to have significantly higher neuronal counts of CA1 and CA2 in the hippocampus, and Purkinje cells in the cerebellum. Conclusions Current findings suggest that atorvastatin increases sphingosine-1-phosphate levels and decreases inflammatory actions which characterize the autism rodent model implemented in this study. These preliminary results have to be confirmed by further experimental and clinical studies.